Cargando…

Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination

Genetic diseases are often caused by nonsense mutations, but only one TRID (translation readthrough inducing drug), ataluren, has been approved for clinical use. Ataluren inhibits release factor complex (RFC) termination activity, while not affecting productive binding of near-cognate ternary comple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shijie, Bhattacharya, Arpan, Ghelfi, Mikel D., Li, Hong, Fritsch, Clark, Chenoweth, David M., Goldman, Yale E., Cooperman, Barry S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076611/ https://www.ncbi.nlm.nih.gov/pubmed/35523781 http://dx.doi.org/10.1038/s41467-022-30080-6

Ejemplares similares

Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms
por: Ng, Martin Y., et al.
Publicado: (2021)

A High-Throughput Assay for In Vitro Determination of Release Factor-Dependent Peptide Release from a Pretermination Complex by Fluorescence Anisotropy—Application to Nonsense Suppressor Screening and Mechanistic Studies
por: Ghelfi, Mikel D., et al.
Publicado: (2023)

Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner
por: Michorowska, Sylwia
Publicado: (2021)

Ataluren suppresses a premature termination codon in an MPS I-H mouse
por: Wang, Dan, et al.
Publicado: (2022)

Effect of Ataluren on dystrophin mutations
por: Berger, Joachim, et al.
Publicado: (2020)

Caffeine boosts Ataluren's readthrough activity
por: Lentini, Laura, et al.
Publicado: (2019)

Treatment with Ataluren for Duchene Muscular Dystrophy
por: Morkous, Sameh S.
Publicado: (2020)

Ataluren treatment of patients with nonsense mutation dystrophinopathy
por: Bushby, Katharine, et al.
Publicado: (2014)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

Long term treatment with ataluren—the Swedish experience
por: Michael, Eva, et al.
Publicado: (2021)

Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
por: Namgoong, John Hyun, et al.
Publicado: (2016)

Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia
por: Djayet, Celia, et al.
Publicado: (2020)

A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays
por: McElroy, Stuart P., et al.
Publicado: (2013)

Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations
por: Samanta, Ananya, et al.
Publicado: (2019)

Real-time assay for testing components of protein synthesis
por: Rosenblum, Gabriel, et al.
Publicado: (2012)

EF-Tu dynamics during pre-translocation complex formation: EF-Tu·GDP exits the ribosome via two different pathways
por: Liu, Wei, et al.
Publicado: (2015)

Structural dynamics of translation elongation factor Tu during aa-tRNA delivery to the ribosome
por: Kavaliauskas, Darius, et al.
Publicado: (2018)

Site-Specific Fluorescent Labeling of RNA Interior Positions
por: Cooperman, Barry S.
Publicado: (2021)

Translocation kinetics and structural dynamics of ribosomes are modulated by the conformational plasticity of downstream pseudoknots
por: Wu, Bo, et al.
Publicado: (2018)

In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren
por: Kong, Ronald, et al.
Publicado: (2020)

Dynamics of translation by single ribosomes through mRNA secondary structures
por: Chen, Chunlai, et al.
Publicado: (2013)

Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes
por: Bolze, Florian, et al.
Publicado: (2017)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy
por: Bitetti, Ilaria, et al.
Publicado: (2021)

Competitive folding of RNA structures at a termination–antitermination site
por: Ait-Bara, Soraya, et al.
Publicado: (2017)

Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder
por: Devinsky, Orrin, et al.
Publicado: (2021)

E. coli elongation factor Tu bound to a GTP analogue displays an open conformation equivalent to the GDP-bound form
por: Johansen, Jesper S, et al.
Publicado: (2018)

Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
por: Finkel, Richard S., et al.
Publicado: (2013)

One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?
por: Ruggiero, Lucia, et al.
Publicado: (2018)

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
por: Dori, Amir, et al.
Publicado: (2021)

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
por: Dori, Amir, et al.
Publicado: (2022)

FRET-Based Identification of mRNAs Undergoing Translation
por: Stevens, Benjamin, et al.
Publicado: (2012)

Site of Resistance or Apparatus of Acquiescence? Tactics at the Bakery
por: Martίnez, José Ciro
Publicado: (2018)

Labeled EF-Tus for Rapid Kinetic Studies of Pretranslocation Complex Formation
por: Liu, Wei, et al.
Publicado: (2014)

Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2018)

Condensin locates at transcriptional termination sites in mitosis, possibly releasing mitotic transcripts
por: Nakazawa, Norihiko, et al.
Publicado: (2019)

Corrigendum: Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2019)

Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study
por: Tiddens, Harm A. W. M., et al.
Publicado: (2020)

Good response to the late treatment with ataluren in a boy with Duchenne muscular dystrophy: could the previous mild course of the disease have affected the outcome?
por: Pasca, Ludovica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nmo1jobldrqnn51p52ti2vog4p